Allozen Pharma Private Limited - Due diligence report

A 360° intelligence report on Allozen Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and …

2019-10-16 Bangalore, Karnataka Active Unlisted
Share
Connect MCP
AP Allozen Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Allozen Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
85/100
Trust Score
Low Risk

Allozen Pharma Private Limited is assessed as Low Risk with a Trust Score of 85/100. Allozen Pharma Private Limited is an active private limited indian non-government company incorporated in 2019, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 27 Jul 2026 from the latest processed filings. Allozen Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
85/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
35/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
80/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 35/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Elevated gearing (D/E 1.42).
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 4 open (29.40 cr) · 1 satisfied (25.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others2 48.0 cr
The Hongkong And Shanghai Banking Corporation Limited2 48.0 cr
Hdfc Bank Limited1 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 3 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
PRAFFUL JAIN 01234567 Director 01/04/2018 6 yrs Approved
ATISH ASHOK JAIN 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 85 · Distress 80
Growth signals & trust indicators
Revenue acceleration: +2.1x over 3 year(s).
Latest year revenue grew 24%.
Asset base grew 0.86 - capacity expansion.
Operating for 6 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Outside liabilities up 61% in a year.
4 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence85/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment62/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 29.40 cr already registered.
  • Compliance record supports lending.
Investor view83/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 3 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
29 Mar 2025
Charge satisfied
Others
01 Feb 2025
Charge created
Others - 25.00 cr
26 Oct 2024
Charge created
Hdfc Bank Limited - 20.01 Lakh
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
30 Nov 2022
Director ceased
ASHOK KUMAR PALRESHA
01 Oct 2022
Director appointed
ATISH ASHOK JAIN (Director)
30 Jun 2022
Charge created
The Hongkong And Shanghai Banking Corporation Limited - 14.00 cr
Charge created
The Hongkong And Shanghai Banking Corporation Limited - 20.00 Lakh
23 Aug 2021
Director ceased
DEEPAK MOOLCHAND JAIN
Director ceased
ASHUTOSH BHERUMAL BHANDARI
Director ceased
YOGESH BHANDARI
27 Feb 2020
Charge created
Others - 15.00 cr
16 Oct 2019
Incorporated
Registered with Roc Bangalore
Director appointed
PRAFFUL JAIN (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 3 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Gorja International Private Limited U45400HR2009PTC039093 Panipat, Haryana, India
Accely Trading Private Limited U52603MH2020PTC343513 Mumbai, Maharashtra, India
Menaka Electricals Private Limited U74999TN2018PTC121667 Chennai, Tamil Nadu, India
Irometal Alloys India Private Limited U27109PN2020PTC193460 Pune City, Maharashtra, India
Pyramid Timber Industries Private Limited U20232DL2008PTC178919 New Delhi, Delhi, India
Kajariaply U36109DL2017PTC324260 New Delhi, Delhi, India
Shivaay Marketing Private Limited U51900DL2018PTC342255 East Delhi, Delhi, India
Saarang International Food & Beverages Private Limited U15122HR2014PTC054101 Kalanwali, Haryana, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Allozen Pharma Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Allozen Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 35/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Allozen Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether Allozen Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Allozen Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Allozen Pharma Private Limited an active company?

Allozen Pharma Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Allozen Pharma Private Limited financially healthy?

Allozen Pharma Private Limited has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.

Should I do business with Allozen Pharma Private Limited?

Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Allozen Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Allozen Pharma Private Limited have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 1 earlier charge(s) stand satisfied.

Is Allozen Pharma Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Allozen Pharma Private Limited?

Its Credit Risk Score is 35/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.